Chief Technology Officer at PROTHELIA INCORPORATED - Milford, MA, US
founder chief strategy officer
Contact Bradley Hodges
Vice President, Clinical Operations
Contact Tristen Moors
Associate Director, Business Development & Strategy
Contact Emily Tess
Senior Director, Nonclinical Development & Toxicology
Contact Cort Cramer
Chief Scientific Officer
Contact Dennis Keefe
Founder CSO
Contact Bradley L.
Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.